Tech Session VII: Delivery to the Nervous System II
Targeted Depletion of CNS-Resident Immune Cells Using a Bispecific Antibody Shuttle
Friday, July 18, 2025
9:27 AM – 9:38 AM EDT
Introduction: Neuroinflammation contributes significantly to the progression of CNS disorders, yet current therapies are limited by their inability to target immune cells within the CNS due to the restrictive blood-brain barrier (BBB). [1] While systemic immunosuppressive therapies offer some benefits, they fail to address CNS-resident immune cells, presenting an unmet clinical need. This study hypothesized that bispecific antibodies engineered to target transferrin receptors (TfR-1) on brain endothelial cells could facilitate BBB transport and enable precise modulation of neuroinflammatory responses. [2]
Learning Objectives:
At the completion of this activity, participants will know
Describe the challenges associated with delivering therapeutics across the blood-brain barrier.
Explain the design and function of bispecific antibodies engineered to target transferrin receptors.
Evaluate the clinical implications of bispecific antibody technology in treating neuroinflammation.
